指南与共识肝病消化内镜消化道出血

肝硬化患者接受上消化道内镜和腹腔穿刺术时凝血病管理:多学科德尔菲法共识中持续存在的差距与共识领域

Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi.
指南 / 共识 · Hepatology · 2024-04-01

该多学科德尔菲法研究针对肝硬化患者腹腔穿刺和上消化道内镜围手术期凝血病管理,从286项候选指标中确定33项最终指标,就国际标准化比值检测、血浆输注、血小板输注及抗血小板药物持续使用等达成部分共识,但治疗性/急诊内镜及抗凝管理未达成共识。

要点

  • 诊断性或治疗性腹腔穿刺及诊断性内镜无需检测国际标准化比值。
  • 所有腹腔穿刺和诊断性内镜应避免输注血浆。
  • 门诊诊断性腹腔穿刺和诊断性内镜预防性输血小板风险大于获益。

核心结论

  • 研究在肝硬化围手术期凝血病管理方面发现许多共识领域,可作为一套共同实践指标的基础。

研究设计与样本

  • 采用改良德尔菲法(3轮评分)的多学科小组共识研究,由11名内容专家组成小组,成员包括介入放射学、输血医学和麻醉学专业学会提名者以及血液学、急诊医学、移植外科和社区实践代表。

主要发现

  • 在286项可能指标中,33项进入最终指标集。
  • 诊断性或治疗性腹腔穿刺及诊断性内镜不要求检测国际标准化比值。
  • 所有腹腔穿刺和诊断性内镜应避免输注血浆;在治疗性或急诊内镜中这些项目未达成共识。
  • 门诊诊断性腹腔穿刺和诊断性内镜预防性输注血小板的风险超过获益;其他检查中血小板计数>20,000/mm³时风险大于获益,低于20,000/mm³时风险是否大于获益不确定。
  • 对是否允许继续或停止全身抗凝未达成共识;每次操作持续使用阿司匹林是允许的;氯吡格雷可用于诊断性和治疗性腹腔穿刺及诊断性内镜。

关键数值与推荐

  • 诊断性或治疗性腹腔穿刺及诊断性内镜不要求检测国际标准化比值(共识指标)。
  • 所有腹腔穿刺和诊断性内镜应避免输注血浆(共识指标)。
  • 门诊诊断性腹腔穿刺和诊断性内镜预防性输注血小板风险超过获益(共识指标)。
  • 其他检查中血小板计数>20,000/mm³时输注血小板风险大于获益(共识指标)。
  • 每次操作持续使用阿司匹林是允许的;氯吡格雷可用于诊断性和治疗性腹腔穿刺及诊断性内镜(共识指标)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 治疗性或急诊内镜中国际标准化比值检测和血浆输注项目未达成共识。
  • 其他检查中血小板计数<20,000/mm³时风险是否大于获益不确定。
  • 是否允许继续或停止全身抗凝未达成共识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with cirrhosis have abnormal coagulation indices such as a high international normalized ratio and low platelet count, but these do not correlate well with periprocedural bleeding risk. We sought to develop a consensus among the multiple stakeholders in cirrhosis care to inform process measures that can help improve the quality of the periprocedural management of coagulopathy in cirrhosis. We identified candidate process measures for periprocedural coagulopathy management in multiple contexts relating to the performance of paracentesis and upper endoscopy. An 11-member panel with content expertise was convened. It included nominees from professional societies for interventional radiology, transfusion medicine, and anesthesia as well as representatives from hematology, emergency medicine, transplant surgery, and community practice. Each measure was evaluated for agreement using a modified Delphi approach (3 rounds of rating) to define the final set of measures. Out of 286 possible measures, 33 measures made the final set. International normalized ratio testing was not required for diagnostic or therapeutic paracentesis as well as diagnostic endoscopy. Plasma transfusion should be avoided for all paracenteses and diagnostic endoscopy. No consensus was achieved for these items in therapeutic intent or emergent endoscopy. The risks of prophylactic platelet transfusions exceed their benefits for outpatient diagnostic paracentesis and diagnostic endosopies. For the other procedures examined, the risks outweigh benefits when platelet count is >20,000/mm 3 . It is uncertain whether risks outweigh benefits below 20,000/mm 3 in other contexts. No consensus was achieved on whether it was permissible to continue or stop systemic anticoagulation. Continuous aspirin was permissible for each procedure. Clopidogrel was permissible for diagnostic and therapeutic paracentesis and diagnostic endoscopy. We found many areas of consensus that may serve as a foundation for a common set of practice metrics for the periprocedural management of coagulopathy in cirrhosis.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Tapper EB, Warner MA, Shah RP, et al. Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi. Hepatology. 2024. PMID: 38557474. doi:10.1097/HEP.0000000000000856

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。